Ensign Peak Advisors Inc Cuts Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Ensign Peak Advisors Inc reduced its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 7.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 564,217 shares of the company’s stock after selling 47,597 shares during the period. Ensign Peak Advisors Inc owned approximately 0.65% of IDEAYA Biosciences worth $14,500,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. R Squared Ltd bought a new stake in shares of IDEAYA Biosciences in the fourth quarter worth about $35,000. Daiwa Securities Group Inc. increased its stake in IDEAYA Biosciences by 44.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company’s stock worth $72,000 after acquiring an additional 853 shares during the last quarter. KBC Group NV raised its holdings in shares of IDEAYA Biosciences by 84.6% during the 4th quarter. KBC Group NV now owns 4,197 shares of the company’s stock worth $108,000 after acquiring an additional 1,923 shares in the last quarter. Cibc World Markets Corp bought a new position in shares of IDEAYA Biosciences during the 4th quarter valued at approximately $203,000. Finally, Mariner LLC grew its holdings in shares of IDEAYA Biosciences by 9.8% in the fourth quarter. Mariner LLC now owns 9,775 shares of the company’s stock valued at $251,000 after purchasing an additional 869 shares in the last quarter. Hedge funds and other institutional investors own 98.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on IDYA. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Stephens restated an “overweight” rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Two research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $53.58.

IDEAYA Biosciences Trading Down 4.5%

NASDAQ IDYA opened at $17.37 on Monday. The stock has a market cap of $1.52 billion, a PE ratio of -5.26 and a beta of 0.26. IDEAYA Biosciences, Inc. has a 12 month low of $13.45 and a 12 month high of $44.42. The company’s 50-day moving average price is $17.74 and its 200-day moving average price is $22.59.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, May 6th. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.07). During the same period last year, the company posted ($0.53) EPS. As a group, sell-side analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.